FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4308766062> ?p ?o ?g. }

• W4308766062 endingPage "830" @default.
• W4308766062 startingPage "817" @default.
• W4308766062 abstract "Abstract Objectives The objective of the current study was to detect plasma profiles of inflammatory cytokines for determining potential biomarkers indicating cancer presence among the anti-TIF1-γ antibody-positive dermatomyositis (DM) patients. Methods Twenty-seven cancer-associated anti-TIF1-γ antibody-positive DM (Cancer TIF1-γ-DM) patients were compared with 20 anti-TIF1-γ antibody-positive DM patients without cancer (Non-cancer TIF1-γ-DM) and 10 healthy controls (HC). The plasma levels of 17 cytokines were determined using the Luminex 200 system. The ability of plasma VEGF-A, TNF-α, CCL2, IL-6, and IFN-γ levels to distinguish the presence of cancer was evaluated through the area under the curve (AUC) analysis. Potential protein interactions of TIF1-γ and the five cytokines were analyzed using the STRING database. Results VEGF-A, TNF-α, CCL2, IL-6, and IFN-γ plasma levels were significantly higher in the Cancer TIF1-γ-DM group, especially those without any anticancer treatment, than those in the non-cancer TIF1-γ-DM and HC groups. Meanwhile, anti-TIF1-γ antibody and the five cytokines could distinguish cancer presence in anti-TIF1-γ antibody-positive DM patients. The STRING network indicated that TIF1-γ potentially interacted with the cytokines. Positive correlations of VEGF-A among CCL2, IL-6, and IFN-γ and between IFN-γ and IL-6 were observed in Cancer TIF1-γ-DM patients. VEGF-A, TNF-α, CCL2, and IL-6 were positively associated with muscle-associated enzymes among the Cancer TIF1-γ-DM patients. Conclusion The present study identified VEGF-A, TNF-α, CCL2, IL-6, and IFN-γ as significant potential biomarkers indicating the presence of cancer and demonstrated a more detailed cytokine profile during diagnosis. These biomarkers could provide better screening strategies and insight into the Cancer TIF1-γ-DM pathogenesis. Key Points • VEGF-A, TNF-α, CCL2, IL-6, and IFN-γ are potential biomarkers of cancer in cancer-associated anti-TIF1-γ antibody-positive dermatomyositis. Graphical abstract" @default.
• W4308766062 created "2022-11-15" @default.
• W4308766062 creator A5038931618 @default.
• W4308766062 creator A5041316143 @default.
• W4308766062 creator A5054536350 @default.
• W4308766062 creator A5057493437 @default.
• W4308766062 creator A5067387552 @default.
• W4308766062 creator A5079899395 @default.
• W4308766062 creator A5081784556 @default.
• W4308766062 creator A5082200177 @default.
• W4308766062 creator A5088592356 @default.
• W4308766062 creator A5090435133 @default.
• W4308766062 date "2022-11-11" @default.
• W4308766062 modified "2023-10-05" @default.
• W4308766062 title "Circulating VEGF-A, TNF-α, CCL2, IL-6, and IFN-γ as biomarkers of cancer in cancer-associated anti-TIF1-γ antibody-positive dermatomyositis" @default.
• W4308766062 cites W184510336 @default.
• W4308766062 cites W1923584930 @default.
• W4308766062 cites W1968504912 @default.
• W4308766062 cites W1972060594 @default.
• W4308766062 cites W1994644835 @default.
• W4308766062 cites W2021355899 @default.
• W4308766062 cites W2044606833 @default.
• W4308766062 cites W2061294496 @default.
• W4308766062 cites W2111356860 @default.
• W4308766062 cites W2131933689 @default.
• W4308766062 cites W2148709599 @default.
• W4308766062 cites W2149932234 @default.
• W4308766062 cites W2165911231 @default.
• W4308766062 cites W2166113386 @default.
• W4308766062 cites W2279973952 @default.
• W4308766062 cites W2294927533 @default.
• W4308766062 cites W2314311014 @default.
• W4308766062 cites W2512680444 @default.
• W4308766062 cites W2744617457 @default.
• W4308766062 cites W2765743865 @default.
• W4308766062 cites W2769178448 @default.
• W4308766062 cites W2786512781 @default.
• W4308766062 cites W2811473109 @default.
• W4308766062 cites W2884906365 @default.
• W4308766062 cites W2888173545 @default.
• W4308766062 cites W2893631054 @default.
• W4308766062 cites W2922272744 @default.
• W4308766062 cites W2946628904 @default.
• W4308766062 cites W2951756816 @default.
• W4308766062 cites W2954782608 @default.
• W4308766062 cites W2965254671 @default.
• W4308766062 cites W2981614976 @default.
• W4308766062 cites W2989921779 @default.
• W4308766062 cites W3008629354 @default.
• W4308766062 cites W3048974945 @default.
• W4308766062 cites W3087422243 @default.
• W4308766062 cites W3120815116 @default.
• W4308766062 cites W3132343671 @default.
• W4308766062 cites W3138332839 @default.
• W4308766062 cites W3153943937 @default.
• W4308766062 cites W3198410084 @default.
• W4308766062 cites W3207293584 @default.
• W4308766062 cites W4206020284 @default.
• W4308766062 cites W4206424764 @default.
• W4308766062 cites W4211050134 @default.
• W4308766062 doi "https://doi.org/10.1007/s10067-022-06425-3" @default.
• W4308766062 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/36357631" @default.
• W4308766062 hasPublicationYear "2022" @default.
• W4308766062 type Work @default.
• W4308766062 citedByCount "1" @default.
• W4308766062 countsByYear W43087660622023 @default.
• W4308766062 crossrefType "journal-article" @default.
• W4308766062 hasAuthorship W4308766062A5038931618 @default.
• W4308766062 hasAuthorship W4308766062A5041316143 @default.
• W4308766062 hasAuthorship W4308766062A5054536350 @default.
• W4308766062 hasAuthorship W4308766062A5057493437 @default.
• W4308766062 hasAuthorship W4308766062A5067387552 @default.
• W4308766062 hasAuthorship W4308766062A5079899395 @default.
• W4308766062 hasAuthorship W4308766062A5081784556 @default.
• W4308766062 hasAuthorship W4308766062A5082200177 @default.
• W4308766062 hasAuthorship W4308766062A5088592356 @default.
• W4308766062 hasAuthorship W4308766062A5090435133 @default.
• W4308766062 hasBestOaLocation W43087660621 @default.
• W4308766062 hasConcept C121608353 @default.
• W4308766062 hasConcept C126322002 @default.
• W4308766062 hasConcept C143998085 @default.
• W4308766062 hasConcept C159654299 @default.
• W4308766062 hasConcept C167734588 @default.
• W4308766062 hasConcept C17991360 @default.
• W4308766062 hasConcept C203014093 @default.
• W4308766062 hasConcept C2778751314 @default.
• W4308766062 hasConcept C71924100 @default.
• W4308766062 hasConceptScore W4308766062C121608353 @default.
• W4308766062 hasConceptScore W4308766062C126322002 @default.
• W4308766062 hasConceptScore W4308766062C143998085 @default.
• W4308766062 hasConceptScore W4308766062C159654299 @default.
• W4308766062 hasConceptScore W4308766062C167734588 @default.
• W4308766062 hasConceptScore W4308766062C17991360 @default.
• W4308766062 hasConceptScore W4308766062C203014093 @default.
• W4308766062 hasConceptScore W4308766062C2778751314 @default.
• W4308766062 hasConceptScore W4308766062C71924100 @default.
• W4308766062 hasIssue "3" @default.
• W4308766062 hasLocation W43087660621 @default.

• next